Research ExplorerPublicationsp16 overexpression and 9p21 deletion are linked to unfavorab...

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer

Standard

p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. / Lebok, Patrick; Roming, Magdalena; Kluth, Martina; Koop, Christina; Ozden, Cansu; Taskin, B; Hussein, K; Lebeau, Annette; Witzel, Isabell; Wölber, Linn; Geist, Stefan; Paluchowski, Peter; Wilke, Christian; Heilenkötter, Uwe; Müller, Volkmar; Schmalfeldt, Barbara; Simon, Ronald; Sauter, Guido; Terracciano, Luigi; Krech, Rainer Horst; von der Assen, Albert; Burandt, Eike.

In: ONCOTARGET, Vol. 7, No. 49, 06.12.2016, p. 81322-81331.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lebok, P, Roming, M, Kluth, M, Koop, C, Ozden, C, Taskin, B, Hussein, K, Lebeau, A, Witzel, I, Wölber, L, Geist, S, Paluchowski, P, Wilke, C, Heilenkötter, U, Müller, V, Schmalfeldt, B, Simon, R, Sauter, G, Terracciano, L, Krech, RH, von der Assen, A & Burandt, E 2016, 'p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer', ONCOTARGET, vol. 7, no. 49, pp. 81322-81331. https://doi.org/10.18632/oncotarget.13227

APA

Lebok, P., Roming, M., Kluth, M., Koop, C., Ozden, C., Taskin, B., Hussein, K., Lebeau, A., Witzel, I., Wölber, L., Geist, S., Paluchowski, P., Wilke, C., Heilenkötter, U., Müller, V., Schmalfeldt, B., Simon, R., Sauter, G., Terracciano, L., ... Burandt, E. (2016). p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. ONCOTARGET, 7(49), 81322-81331. https://doi.org/10.18632/oncotarget.13227

Vancouver

Lebok P, Roming M, Kluth M, Koop C, Ozden C, Taskin B et al. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. ONCOTARGET. 2016 Dec 6;7(49):81322-81331. https://doi.org/10.18632/oncotarget.13227

Bibtex

@article{a92cae898caa40d5a90bcdf9265ba374,
title = "p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer",
abstract = "Overexpression of the p16 tumor suppressor, but also deletion of its gene locus 9p21, is linked to unfavorable tumor phenotype and poor prognosis in breast cancer. To better understand these contradictory observations, and to clarify the prognostic impact of p16 expression and 9p21 deletion, a tissue microarray (TMA) with 2,197 breast cancers was analyzed by fluorescence in-situ hybridization and immunohistochemistry (FISH) for 9p21 deletion and p16 expression. p16 immunostaining was weak in 25.6%, moderate in 7.1%, and strong in 12.7% of 1,684 evaluable cancers. Strong p16 staining was linked to advanced tumor stage (p = 0.0003), high-grade (p < 0.0001), high tumor cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p < 0.0001 each), and shorter overall survival (p = 0.0038). 9p21 deletion was found in 15.3% of 1,089 analyzable breast cancers, including 1.7% homozygous and 13.6% heterozygous deletions. 9p21 deletion was linked to adverse tumor features, including high-grade (p < 0.0001) and nodal positive cancers (p = 0.0063), high cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p ≤ 0.0006), and HER2 amplification (p = 0.0078). Patient outcome was worse in 9p21 deleted than in undeleted cancers (p = 0.0720). p16 expression was absent in cancers harboring homozygous 9p21 deletions, but no difference in p16 expression was found between cancers with (59.2% p16 positive) and without heterozygous 9p21 deletion (51.3% p16 positive, p = 0.0256). In summary, p16 expression is unrelated to partial 9p21 deletion, but both alterations are linked to aggressive breast cancer phenotype. High-level p16 expression is a strong predictor of unfavorable disease course in breast cancer.",
author = "Patrick Lebok and Magdalena Roming and Martina Kluth and Christina Koop and Cansu Ozden and B Taskin and K Hussein and Annette Lebeau and Isabell Witzel and Linn W{\"o}lber and Stefan Geist and Peter Paluchowski and Christian Wilke and Uwe Heilenk{\"o}tter and Volkmar M{\"u}ller and Barbara Schmalfeldt and Ronald Simon and Guido Sauter and Luigi Terracciano and Krech, {Rainer Horst} and {von der Assen}, Albert and Eike Burandt",
year = "2016",
month = dec,
day = "6",
doi = "10.18632/oncotarget.13227",
language = "English",
volume = "7",
pages = "81322--81331",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "49",

}

RIS

TY - JOUR

T1 - p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer

AU - Lebok, Patrick

AU - Roming, Magdalena

AU - Kluth, Martina

AU - Koop, Christina

AU - Ozden, Cansu

AU - Taskin, B

AU - Hussein, K

AU - Lebeau, Annette

AU - Witzel, Isabell

AU - Wölber, Linn

AU - Geist, Stefan

AU - Paluchowski, Peter

AU - Wilke, Christian

AU - Heilenkötter, Uwe

AU - Müller, Volkmar

AU - Schmalfeldt, Barbara

AU - Simon, Ronald

AU - Sauter, Guido

AU - Terracciano, Luigi

AU - Krech, Rainer Horst

AU - von der Assen, Albert

AU - Burandt, Eike

PY - 2016/12/6

Y1 - 2016/12/6

N2 - Overexpression of the p16 tumor suppressor, but also deletion of its gene locus 9p21, is linked to unfavorable tumor phenotype and poor prognosis in breast cancer. To better understand these contradictory observations, and to clarify the prognostic impact of p16 expression and 9p21 deletion, a tissue microarray (TMA) with 2,197 breast cancers was analyzed by fluorescence in-situ hybridization and immunohistochemistry (FISH) for 9p21 deletion and p16 expression. p16 immunostaining was weak in 25.6%, moderate in 7.1%, and strong in 12.7% of 1,684 evaluable cancers. Strong p16 staining was linked to advanced tumor stage (p = 0.0003), high-grade (p < 0.0001), high tumor cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p < 0.0001 each), and shorter overall survival (p = 0.0038). 9p21 deletion was found in 15.3% of 1,089 analyzable breast cancers, including 1.7% homozygous and 13.6% heterozygous deletions. 9p21 deletion was linked to adverse tumor features, including high-grade (p < 0.0001) and nodal positive cancers (p = 0.0063), high cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p ≤ 0.0006), and HER2 amplification (p = 0.0078). Patient outcome was worse in 9p21 deleted than in undeleted cancers (p = 0.0720). p16 expression was absent in cancers harboring homozygous 9p21 deletions, but no difference in p16 expression was found between cancers with (59.2% p16 positive) and without heterozygous 9p21 deletion (51.3% p16 positive, p = 0.0256). In summary, p16 expression is unrelated to partial 9p21 deletion, but both alterations are linked to aggressive breast cancer phenotype. High-level p16 expression is a strong predictor of unfavorable disease course in breast cancer.

AB - Overexpression of the p16 tumor suppressor, but also deletion of its gene locus 9p21, is linked to unfavorable tumor phenotype and poor prognosis in breast cancer. To better understand these contradictory observations, and to clarify the prognostic impact of p16 expression and 9p21 deletion, a tissue microarray (TMA) with 2,197 breast cancers was analyzed by fluorescence in-situ hybridization and immunohistochemistry (FISH) for 9p21 deletion and p16 expression. p16 immunostaining was weak in 25.6%, moderate in 7.1%, and strong in 12.7% of 1,684 evaluable cancers. Strong p16 staining was linked to advanced tumor stage (p = 0.0003), high-grade (p < 0.0001), high tumor cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p < 0.0001 each), and shorter overall survival (p = 0.0038). 9p21 deletion was found in 15.3% of 1,089 analyzable breast cancers, including 1.7% homozygous and 13.6% heterozygous deletions. 9p21 deletion was linked to adverse tumor features, including high-grade (p < 0.0001) and nodal positive cancers (p = 0.0063), high cell proliferation (p < 0.0001), negative hormone receptor (ER/PR) status (p ≤ 0.0006), and HER2 amplification (p = 0.0078). Patient outcome was worse in 9p21 deleted than in undeleted cancers (p = 0.0720). p16 expression was absent in cancers harboring homozygous 9p21 deletions, but no difference in p16 expression was found between cancers with (59.2% p16 positive) and without heterozygous 9p21 deletion (51.3% p16 positive, p = 0.0256). In summary, p16 expression is unrelated to partial 9p21 deletion, but both alterations are linked to aggressive breast cancer phenotype. High-level p16 expression is a strong predictor of unfavorable disease course in breast cancer.

U2 - 10.18632/oncotarget.13227

DO - 10.18632/oncotarget.13227

M3 - SCORING: Journal article

C2 - 27835607

VL - 7

SP - 81322

EP - 81331

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 49

ER -